Guideline-directed management and therapy (GDMT) for the prevention of postpartum cardiac dysfunction in preeclamptic African American women

项目总结/摘要 非裔美国妇女患产后高血压的可能性高出60%， 比白色女性更容易死于先兆子痫。无论是在怀孕期间还是总体上， 非裔美国妇女更严重，在生活中出现更早。与其他民族相比， 在种族群体中，非洲裔美国妇女的高血压相关终末器官死亡率较高， 比如心力衰竭和中风然而，目前还没有经过验证的干预措施来预防或减轻 产后高血压性心脏病的发展。 使用指南导向的药物治疗产后非洲人的随机机制临床试验 美国妇女与先兆子痫，我们将提前了解心功能不全的先兆子痫及其 可能的治疗。我们追求一个特定的目标来回答这些问题。AIM 1是一项随机试验， 指南指导的药物治疗是否能改善心脏功能和降低血压， 产后患有先兆子痫的非裔美国妇女。该项目在方法上进行了创新， 极大地推进了我们对非裔美国人发病率和死亡率重要原因的理解 妇女

Project Summary/Abstract African American women are 60% more likely to have postpartum hypertension and are nearly three times more likely to die from preeclampsia than white women. Both during pregnancy and overall, hypertension in African American women is more severe and presents earlier in life. In addition, compared to other ethnic- racial groups, African American women have higher mortality rates from hypertension-related end-organ damage like heart failure and stroke. Currently, however, no proven interventions exist to prevent or mitigate the development of hypertensive heart disease during the postpartum period. Using a randomized mechanistic clinical trial of guideline-directed medical therapy for postpartum African American women with preeclampsia, we will advance knowledge of cardiac dysfunction in preeclampsia and its possible treatments. We pursue a specific aim to answer these questions. AIM 1 is a randomized trial to test whether guideline-directed medical therapy improves cardiac function and decreases blood pressure in postpartum African American women with preeclampsia. This project innovates methodologically to dramatically advance our understanding of a significant cause of morbidity and mortality in African American women.